Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Zevra Therapeutics (ZVRA – Research Report) and keeping the price target at $25.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jason McCarthy has given his Buy rating due to a combination of factors, primarily driven by Zevra Therapeutics’ strong financial performance and strategic initiatives. The company reported a significant increase in net revenue for the first quarter of 2025, surpassing both consensus and forecasted figures, largely due to the successful launch of Miplyffa. This new drug, approved in late 2024, has shown promising early adoption with substantial patient enrollment and a robust pricing strategy, indicating a potential for steep revenue growth.
Additionally, Zevra’s financial stability is reinforced by the sale of its priority review voucher, providing substantial non-dilutive funding. The company’s strategic focus on expanding Miplyffa’s market presence in Europe and its ongoing efforts in developing treatments for rare diseases further support the positive outlook. Despite some challenges with Olpruva’s slower-than-expected sales growth, the overall financial health and strategic direction of Zevra Therapeutics underpin McCarthy’s optimistic Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Medicus Pharma Ltd, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -21.7% and a 26.41% success rate on recommended stocks.
In another report released yesterday, Citizens JMP also maintained a Buy rating on the stock with a $19.00 price target.